Comparative Pharmacology
Head-to-head clinical analysis: AVZIVI versus BYOOVIZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVZIVI versus BYOOVIZ.
AVZIVI vs BYOOVIZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avizivi (avelumab) is a human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors. This restores anti-tumor immune responses, including T-cell activation and proliferation, by reversing PD-L1-mediated inhibition.
BYOOVIZ (bevacizumab-maly) is a vascular endothelial growth factor (VEGF) inhibitor that binds to VEGF-A and prevents its interaction with receptors VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
IV 200 mg over 30 minutes on Day 1 of a 21-day cycle, in combination with paclitaxel and carboplatin; continue until disease progression or unacceptable toxicity.
0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection once every 4 weeks (monthly). Dose adjustment is not recommended.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; prolonged to 24–48 h in moderate-to-severe renal impairment.
20 days (range 11–50 days) in patients; supports every-2- or 3-week dosing. Longer half-life in bevacizumab compared to other monoclonal antibodies due to FcRn-mediated recycling.
Primarily renal excretion as unchanged drug (~70%) and glucuronide conjugate (~30%); biliary/fecal excretion accounts for <5%.
Bevacizumab (BYOOVIZ) is eliminated primarily via proteolytic catabolism, not renal or biliary excretion. No significant intact drug is excreted in urine or feces.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor